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BACKGROUND: Patients harbouring the UGT1A1*28/*28 genotype are at risk of severe toxicity with the standard irinotecan dose.
However, this dose is considerably lower than the dose that can be tolerated by UGT1A1*1/*1 and *1/*28 patients. This randomised
phase II trial evaluated the efficacy and safety of the FOLFIRI regimen with high-dose irinotecan (HD-FOLFIRI) in metastatic
colorectal cancer patients.
METHODS: Eighty-two patients with the UGT1A1*1/*1 or the *1/*28 genotype were randomised to receive HD-FOLFIRI versus
FOLFIRI. Patients with the UGT1A1*28/*28 genotype were excluded. In the experimental group, the irinotecan dose was 300mg/m2
for UGT1A1*1/*1 and 260 mg/m2 for *1/*28 patients. In the control group, the dose was 180 mg/m2. We analysed the overall
response rate (ORR), toxicity, and survival.
RESULTS: The ORR was significantly higher in the HD-FOLFIRI group (67.5 versus 43.6%; p= 0.001 OR: 1.73 [95% CI:1.03–2.93]).
Neutropenia (17.7%), diarrhoea (5.1%), and asthenia (5.1%) were the most common grade 3–4 toxicity. No differences were
observed in severe toxicity (22.5% versus 20.5%), dose reduction (22.5% versus 28.2%), or prophylactic G-CSF (17.5% versus 12.8%).
No difference in survival was found.
CONCLUSIONS: Patients with the UGT1A1*1/*1 and *1/*28 genotypes can receive high doses of irinotecan to achieve a more
favourable ORR without significant adverse events.
British Journal of Cancer (2019) 120:190–195; https://doi.org/10.1038/s41416-018-0348-7
INTRODUCTION
Colorectal cancer (CRC) is the second most frequent neoplasm in
industrialised countries. Worldwide, it is the fourth deadliest type
of cancer. At initial diagnosis, around 30% of patients have
inoperable or metastatic disease, and >50% of patients will receive
chemotherapy at some stage of the disease.1,2 Current cytotoxic
agents are fluoropyrimidine-based regimens in combination with
oxaliplatin or irinotecan.3
Irinotecan (CPT11) inhibits topoisomerase I, an enzyme needed
to separate the DNA double helix during replication and
transcription.4 This inhibition leads to cell death and is the basis
of its antineoplastic effect. Irinotecan is converted to an active
metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38) by a carbox-
ylesterase, and finally metabolised through the action of uridine
diphosphate glucuronosyltransferase (UGT) enzymes. The predo-
minant enzyme is UGT1A1, the enzyme that conjugates bilirubin.5
In the promoter region of the UGT1A1 gene, an extra TA
dinucleotide characterises the genotype associated with Gilbert’s
syndrome (chronic non-conjugated hyperbilirubinemia due to
reduced UGT1A1 activity). The presence of this polymorphism
(TA7) results in the UGT1A1*28 variant allele instead of the
dominant allele of 6 TA repeats (UGT1A1*1). Patients who are
homozygous for this variant (UGT1A1*28/*28) have less enzymatic
activity and are predisposed to develop myelosuppression and
severe diarrhoea when treated with irinotecan.6–12 Premature
drug suspension and dose reduction as well as administration
delays due to toxicity can decrease antitumour activity. Therefore,
serious toxicity rates that decrease survival can be anticipated
through genetic analysis of patients prior to treatment, thereby
optimising and personalising irinotecan dosing. The United States
of America Food and Drug Administration recognises the
importance of UGT1A1 pharmacogenetics in predicting toxicity
to irinotecan and describes the association between reduced
enzymatic activity of the UGT1A1*28 allele and neutropenia after
drug administration in their summary of product characteristics.
The recommendation is to reduce the dose of irinotecan in
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homozygous patients.13 Despite the good will of this recommen-
dation, however, the exact dose reduction needed to limit drug
toxicity is not specified for *28/*28 patients.
In a previous study (EC07/90232), we classified patients with
metastatic CRC (mCRC) treated with first-line chemotherapy
(FOLFIRI regimen) according to their UGT1A1 genotype. The goal
was to predict, diminish, and/or avoid toxicity and improve the
therapeutic effect of chemotherapy. This optimisation was
based on administering different doses depending on the
genotype of the UGT1A1 gene. The results showed that the
recommended dose of irinotecan within the FOLFIRI regimen
(180 mg/m2) was considerably lower than the dose tolerated by
UGT1A1*1/*1 and *1/*28 patients.14 These findings validated the
results reported by an Italian group who performed a clinical
phase I irinotecan dose-escalation trial according to the UGT1A1
genotype in mCRC patients treated with FOLFIRI.15 Based on
these two studies, it has been proposed to individualise
irinotecan dosing according to the UGT1A1 status so as to
optimise treatment efficacy and tolerability. However, whether
genotype-driven dosing will lead to differences in outcome has
yet to be tested prospectively. For these reasons, the main
objectives of the present randomised phase II trial were to
evaluate the efficacy and safety of the FOLFIRI regimen with
high-dose irinotecan (HD-FOLFIRI) in mCRC patients with a
favourable UGT1A1 genotype (homozygous wild type *1/*1 and
heterozygous *1/*28), while excluding patients genetically at
risk for toxicity (*28/*28).
METHODS
Study design
This randomised, multicentre, open-label, non-blinded phase II
study was conducted in three hospitals in Spain: Hospital de la
Santa Creu i Sant Pau, Barcelona; Hospital Universitario Mutua
Terrassa, Terrassa; and Hospital de Mataró, Mataró, Barcelona. The
protocol was approved by the institutional review board at each
participating centre. All patients signed a written informed
consent form before entering the study. The clinicaltrials.gov
identifier was NCT01639326.
Patient eligibility
Patients with histologically confirmed diagnosis of mCRC and
measurable disease defined via RECIST (Response Evaluation
Criteria in Solid Tumour; version 1.1) were enrolled. Eligibility
criteria were: UGT1A1*1/*1 or *1/*28 genotypes, no prior
chemotherapy for metastatic disease, age ≥18–< 76 years, The
Eastern Cooperative Oncology Group (ECOG) performance
status of 0 or 1, absolute neutrophil count ≥1500/μl, platelets
≥100,000/μl, creatinine clearance <1.5× the upper limit of normal
(ULN), alanine transaminase and aspartate aminotransferase <2.5×
the ULN ( < 5× the ULN in the presence of liver metastases), and
total serum bilirubin ≤1.5 mg/dl. Patients with the UGT1A1*28/*28
genotype or carriers of other UGT1A1 alleles (*6, *36 (TA5), *37
(TA8)) were not eligible.
Randomisation and drug administration
Between June 2012 and October 2016, patients were rando-
mised 1:1 to receive HD-FOLFIRI (experimental group) versus
FOLFIRI (control group) every 2 weeks. Treatment allocation was
conducted using block randomisation and stratified by centre.
The Statistical Package for Social Sciences, Version 19.0 (SPSS Inc.,
Chicago, IL, USA) was used. Irinotecan doses for UGT1A1*1/*1
and *1/*28 patients in the experimental group were 300 and
260mg/m2, respectively. These doses were chosen based on our
previous phase I trial, in which a dose ≥260 mg/m2 was an
independent predictor of a better response in mCRC patients
with the *1/*1 or *1/*28 UGT1A1 genotypes.14 The standard
irinotecan dose of 180mg/m2 was administered in the control
group. Irinotecan was administered as an intravenous infusion
over 90 min on days 1 and 15, with leucovorin 400mg/m2
administered concomitantly. 5-Fluorouracil was administered as a
400mg/m2 bolus immediately after the irinotecan infusion,
followed by 2400mg/m2 over a 46-h continuous infusion on days
1 and 15. A cycle was 28 days. Before irinotecan was started,
patients were pretreated with atropine 0.5 mg, dexamethasone
20mg, and granisetron 1mg. Diarrhoea was promptly treated at
onset with oral intake of loperamide 4mg, and oral intake of 2 mg
for any further episodes. Granulocyte-colony stimulating factors
(G-CSF) were allowed in patients who had grade ≥3 neutropenia
during previous cycles. Treatment was continued until disease
progression, unacceptable toxicity, withdrawal of consent, or
investigator’s decision, whichever was earlier. To avoid potential
bias regarding the primary objectives of the study, biological
agents were not allowed.
Study objectives
The primary objectives were: (1) to determine the effect of higher
doses of irinotecan on the efficacy of FOLFIRI as assessed by
overall response rate (ORR); and (2) to evaluate safety according to
the NCI Common Terminology Criteria for Adverse Events (version
3.0). Objective tumour response was evaluated by the investigator
at each centre using the modified RECIST (version 1.1); no
independent review was performed. Tumour response was
evaluated every 10 weeks (±2 weeks) according to the standard
of care at each centre. Secondary objectives were progression-free
survival (PFS) and overall survival (OS). PFS was defined from the
time of drug administration to the occurrence of progressive
disease or death, whichever occurred first. OS was defined from
the time of drug administration to the date of death. Patients not
meeting the criteria by the cutoff date were censored at the last
contact date.
Genotyping assays
Genomic DNA was extracted from peripheral leukocytes by the
salting-out procedure.16 The TA index of the UGT1A1 promoter
was genotyped by fragment sizing. Polymerase chain reaction
was performed in a total volume of 25 µl containing template
DNA (80 ng/µl), according to Monaghan et al.17 The primers
used were a forward primer that was modified by the addition
of a 50 fluorescent-labelled FAM and an unlabelled reverse
primer (UGT-FAM_F; 50-GTCACGTGACACAGTCAAAC-30, UGT_R
50-TTTGCTCCTGCCAGAGGTT-30). The PCR product (TA*1, 98 bp;
TA*28, 100 bp), the internal size standard, and Hi-Di formamide
(GeneScan 500, Applied Biosystems, Foster City, CA, USA) were
mixed. The samples were then run in the ABI Prism 3100
Genetic Analyzer (Applied Biosystems). Fragment sizes were
determined by comparison with the internal standard GeneScan
500 using the local Southern algorithm and analysed by
the GeneMapper software version 3.5 (Applied Biosystems).
Homozygous-dominant and heterozygous- and homozygous-
recessive sequenced samples were included on every run as a
quality control. Genotypes were assigned based on the number
of TA repeats in each allele (i.e., TA*1/TA*1, TA*1/TA*28, and
TA*28/TA*28).
KRAS and NRAS mutations in exons 2, 3, and 4 and BRAF V600E
mutation were assessed on tumour DNA. Genomic DNA was
extracted using the QIAamp DNA FFPE Tissue Kit (Qiagen, Hilden,
Germany) as specified by the manufacturer’s instructions. Muta-
tional analysis was performed using standard PCR conditions and
primers for exons 2, 3, and 4 of KRAS and NRAS genes and for exon
15 of BRAF gene. The thermal cycling conditions were an initial
12 min at 94°C, followed by 40 cycles of 45 s at 94°C, 45 s at primer
annealing temperature of 55°C, 10 min at 72°C, and a final
extension of 10 min at 72°C. Each sample underwent capillary
electrophoresis on an ABI 3500 Genetic Analyzer (Applied
Biosystems).
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All data were analysed using the Statistical Package for Social
Sciences, Version 19.0, software (SPSS Inc., Chicago, IL, USA). ORR
(complete+partial response) was compared between groups
using chi-square or Fisher’s exact test for Count Data. Based on
the report from Van Cutsem et al., the ORR was reported as 38.7%
for the FOLFIRI regimen.18 An estimated difference to the order of
30% was assumed between the control and the experimental
groups. The target sample size was therefore determined to be 96
patients, distributed between the two groups. The effects of the
irinotecan dose on PFS and OS were estimated using the
Kaplan–Meier estimator, and differences were tested using the
log-rank test. For all comparisons, a two-sided p value <0.05 was
considered significant, so the level was set at 5% (α= 0.05) and
the β level was set at 20% (β= 0.20).
RESULTS
Patient population
Between June 2012 and October 2016, the UGT1A1 genotype was
analysed in mCRC patients (Fig. 1). Owing to 4 years of slower-than
anticipated accrual, the trial was terminated early. Eighty-two
patients harbouring UGT1A1*1/*1 or *1/*28 genotypes were
enrolled from the three centres, with 41 patients randomly
assigned to HD-FOLFIRI (experimental group) and 41 patients to
FOLFIRI (control group). Three patients were not included in the
final study because they did not receive the pre-planned dose for
the endpoint analyses. Therefore, 79 patients were evaluated for
toxicity and for response to treatment. Patient characteristics are
summarised in Table 1.
Efficacy
Table 2 shows the results of the tumour response per-protocol
analysis. The ORR of patients treated with HD-FOLFIRI was
significantly higher than in patients treated with FOLFIRI (67.5%
versus 43.6%; p= 0.001 odds ratio (OR): 1.73 [95% confidence
interval (CI): 1.03–2.93]). In the intention to treat analysis, the ORR
was 65.9% in the experimental group versus 43.9% in the control
group (p= 0.046 OR: 1.64 [95% CI: 0.99–2.72]). There were no
interactions between ORR and clinical characteristics (sex, age,
ECOG, tumour location, or synchronous disease). Metastatic
surgical resection was performed in 15 patients (22.5% in HD-
FOLFIRI and 15.4% in FOLFIRI) and was associated with ORR (29.5%
versus 5.7%; p= 0.007).
There were no interactions between ORR and UGT1A1 or RAS
status (Table 2). However, when BRAF mutated tumours were
considered, the ORR was 41.7% in the HD-FOLFIRI group versus no
objective response in the control group (p= 0.003).




169 did not meet study criteria
1 declined participation
41 assigned to HD-FOLFIRI group 41 assigned to control group
41 patients included in the ITT
analysis
40 patients included in the safety and




41 patients included in the ITT
analysis




1 death for study
disease
Fig. 1 CONSORT diagram
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Survival
The median follow-up period was 18 months (range,
1.8–45 months). The cutoff date for PFS and OS was December
2016. At the time of analysis, 89% of the patients had progressed
(90% in the experimental group and 87% in the control group).
The median PFS and OS were 8.6 and 26 months in the
experimental group (HD-FOLFIRI) and 8.2 and 17.6 months in
the control group (FOLFIRI) (p= 0.46 hazard ratio (HR) 0.84 [95%
CI: 0.52–1.35] and p= 0.74 HR 0.90 [95% CI: 0.49–1.67], respec-
tively) (Supplementary Figure 1).
PFS was significantly associated with ECOG performance status
(9.9 months in ECOG 0 versus 7.2 months in ECOG 1) and
metastatic resection (15.5 months in patients who underwent
surgery versus 7.8 months in the remaining cases). In terms of OS,
patients with metastatic surgery achieved a better outcome than
patients who did not undergone surgery (median not reached
versus 18.4 months).
No statistically significant difference in PFS or OS was found
between the experimental and control groups according to RAS or
BRAF status. In RAS/BRAF wild-type tumours, the median PFS and
OS were 9.8 versus 8.6 months and 29 versus 17 months,
respectively. In RAS-mutated tumours, the median PFS and OS
were 8.5 versus 8.1 months and 14 versus 17.6 months,
respectively. In BRAF-mutated tumours, the median PFS and
OS were 8.3 versus 7.6 months and 22 versus 11.7 months,
respectively.
Table 3 shows the results of the multivariate survival analysis.
Multivariate analysis showed a significant association between
metastatic resection with both PFS and OS. When patients
undergoing metastasectomy were excluded, BRAF- and RAS-
mutated tumours had a shorter PFS and OS than wild-type
tumours (Table 4).
Toxicity
Table 5 summarises the toxicity data available for the 79 patients
who received treatment. The non-haematological toxicities that
were frequently reported were asthenia and adverse gastrointest-
inal effects, such as diarrhoea and nausea/vomiting. With regard
to haematological toxicities, the most frequent were anaemia,
neutropenia, and leukopenia. Most of the toxicities were grade 1
or 2. No significant differences in grade 3–4 toxicities were
observed between patients treated with HD-FOLFIRI or standard
irinotecan dose (FOLFIRI): diarrhoea (2.5% versus 7.7%), asthenia
(5% versus 5.1%), leukopenia (7.5% versus 2.6%), and neutropenia
(15% versus 20.5%). Febrile neutropenia was observed in 2
patients in each arm (5% versus 5.1%). No differences were
observed in serious adverse events (22.5% versus 20.5%), dose
reduction (22.5% versus 28.2%), or prophylactic use of G-CSF
(17.5% versus 12.8%) irrespectively of irinotecan dose.
DISCUSSION
In this study, we continued our line of research by conducting a
randomised phase II trial to evaluate the efficacy and safety of the
FOLFIRI regimen with HD-FOLFIRI as first-line therapy in patients
with mCRC. Our findings confirmed that HD-FOLFIRI increased
ORR without adding toxicity in patients with a favourable UGT1A1
genotype (*1/*1 or *1/*28).
Previous prospective studies have shown that the recom-
mended dose of 180mg/m2 for irinotecan in the FOLFIRI regimen
is considerably lower than the dose that can be tolerated by non-
UGT1A1*28/*28 mCRC patients. In a Caucasian population study,
Toffoli et al.15 established that 370mg/m2 in *1/*1 genotype and
310mg/m2 in *1/*28 genotype can be safely administered every
2 weeks in patients undergoing first-line treatment for mCRC
treated with FOLFIRI. Similar maximum tolerated doses (MTD)












*1/*1 37 (46.8%) 13 (32.5%) 24 (61.5%) 0.01




63 [40–77] 62 [48–75] 64 [40–77] 0.32
Sex
Male 49 (62%) 23 (57.5%) 26 (66.7%) 0.41
Female 30 (38%) 17 (42.5%) 13 (33.3%)
ECOG performance status
0 38 (48.1%) 17 (42.5%) 21 (53.8%) 0.16
1 39 (49.4%) 23 (57.5%) 16 (41%)
2 2 (2.5%) 2 (5.1%)
Primary site
Rightb 22 (27.8%) 9 (22.5%) 13 (33.3%) 0.11
Left 36 (45.6%) 16 (40%) 20 (51.3%)
Rectum 20 (25.3%) 14 (35%) 6 (15.4%)
Missing 1 (1.3%) 1 (2.5%) —
Metastatic development
Synchronic 62 (78.5%) 31 (77.5%) 31 (79.5%) 0.83




10.6 [3–23] 10.6 [3–23] 10.5 [4–20] 0.9
RAS and BRAF status
Wild type 36 (45.6%) 18 (45%) 18 (46.1%) 1.00
RAS mutant 30 (38%) 15 (37.5%) 15 (38.5%)
BRAF mutant 12 (15.2%) 6 (15%) 6 (15.4%)
Unknown 1 (1.2%) 1 (2.5%) —
aPatients who received at least one dose of protocol therapy
bThree patients with transverse colon (one in the HD-FOLFIRI group and
two in the control group)
Table 2. Efficacy data: response rate in the overall population and
according to UGT1A1 and RAS/BRAF genotypes
Response rate p Value
CR+ PR (%) SD (%) PD (%)
Overall population, N= 79 44 (55.7) 20 (25.3) 15 (19) 0.001
HD-FOLFIRI group, N= 40 27 (67.5) 3 (7.5) 10 (25)
Control group, N= 39 17 (43.6) 17 (43.6) 5 (12.8)
UGT1A1 genotype
*1/*1 and *1/*28 N= 79 44 (55.7) 20 (25.3) 15 (19) 0.147
*1/*1 N= 37 17 (46) 13 (35.1) 7 (18.9)
*1/*28 N= 42 27 (64.3) 7 (16.7) 8 (19)
RAS and BRAF genotype
Wild type N= 36 21 (58.3) 9 (25) 6 (16.7) 0.648
RAS mutant N= 30 17 (56.7) 6 (20) 7 (23.3)
BRAF mutant N= 12 5 (41.7) 5 (41.7) 2 (16.6)
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(390mg/m2 in *1/*1 and 340mg/m2 *1/*28 patients) were
validated the following year in a study conducted by our group.14
In an Asian population, in addition to UGT1A1*28, the variant
UGT1A1*6 has been associated with significantly increased related
toxicities. In a phase I study, Korean patients were genotyped for
UGT1A1 and stratified according to the number of defective alleles
(DA): *28 and/or *6. The recommended doses were 300 (0 DA), 270
(1 DA), and 150 (2 DA) mg/m2.19
The effect of adding a biologic drug to genotype-guide dosing
of FOLFIRI has recently been explored. Two initial retrospective
studies in Asian patients were performed by the same group of
investigators. They showed that patients with mCRC with pre-
therapeutic UGT1A1 genotyping and subsequent irinotecan dose
escalation can achieve a more favourable response and outcome
without a significant increase in toxicity while using the FOLFIRI-
plus-bevacizumab regimen.20,21
More recently, Toffoli et al. published a dose-finding study in
first-line mCRC patients treated with FOLFIRI plus bevacizumab to
establish the MTD of irinotecan in *1/*1 and *1/*28 patients.22
Again, the MTD of irinotecan was 310mg/m2 for UGT1A1*1/*1
patients and 260mg/m2 for *1/*28 patients. The most common
dose-limiting toxicities were neutropenia (46%) and diarrhoea
(38%), but 65% of the patients treated at the MTD did not require
a reduction of irinotecan. These authors also demonstrated that
bevacizumab did not alter the pharmacokinetics of irinotecan.
High-dose FOLFIRI (irinotecan 260 mg/m2 for UGT1A1*1/*1 and
*1/*28 genotypes and 220 mg/m2 for UGT1A1*28/*28 genotypes)
combined with cetuximab has been explored in a multicentre
phase II study (ERBIFORT) in patients with potentially resectable
liver metastases of CRC.23 This regimen yielded high response
rates and enabled complete resection of hepatic metastases in
most patients. Thanks to the irinotecan dose adaptation according
to UGT1A1 pharmacogenomics status, this treatment schedule was
less toxic yet as effective as the intense combination of
FOLFIRINOX plus cetuximab reported by Assenat et al. in a phase
II trial.24
It is now widely accepted that the dosing recommendations
obtained from traditional, non-genotype-directed clinical trials
should be revised in light of validated genetic markers of toxicity
risk. The lack of patient stratification based on genotype might
result in significant underdosing of patient subgroups. However,
phase II–III clinical trials are required to determine whether these
irinotecan genotype-guided doses—with or without a biological
agent—imply a higher antitumour efficacy.
To our knowledge, the present work is the first randomised
phase II trial to show higher antitumour efficacy when a
genotype-guided dose of irinotecan is considered. It should be
noted that this scheme not only increases the response rate and
metastasis surgery but also improves efficacy in patients with
worse prognosis, such as mutated BRAF. However, the
Table 3. Multivariate survival analysis
Overall population, N= 79 HD-FOLFIRI group, N= 40 Control group, N= 39 HR [95% CI] p Value
mPFS (months) [95% CI] 8.6 [8–9.2] 8.6 [7.9–9.4] 8.2 [6.8–9.6] 0.84 [0.52–1.35] 0.46
mOS (months) [95% CI] 26 (15–37) 26 [16.7–35.2] 17.6 [1.8–33.4] 0.90 [0.49–1.67] 0.74
Table 4. Survival analyses according to RAS and BRAF status
RAS and BRAF wild type, N= 30ª RAS mutant, N= 24ª BRAF mutant, N= 8ª
mPFS (months) [95% CI] 8.7 [7.2–10.2] 6.7 [3.3–10.2] 4.3 [0.0–10.1]
mOS (months) [95% CI] 25.9 [10.7–41.1] 16.3 [11.3–21.2] 13.8 [1.1–16.5]
aPatients undergoing metastasectomy were excluded
Table 5. Safety data
Overall population HD-FOLFIRI group Control group
N= 79, N (%) N= 40, N (%) N= 39, N (%)
All Grade 3–4 All Grade 3–4 All Grade 3–4
Haematological toxicity
Anaemia 53 (67.1) 1 (1.3) 27 (67.5) 0 (0) 26 (66.7) 1 (2.6)
Leukopenia 21 (26.6) 4 (5.1) 10 (25) 3 (7.5) 11 (28.2) 1 (2.6)
Neutropenia 40 (50.6) 14 (17.7) 20 (50) 6 (15) 20 (51.3) 8 (20.5)
Febrile neutropenia 4 (5.1) 4 (5.1) 2 (5) 2 (5) 2 (5.1) 2 (5.1)
Thrombocythemia 5 (6.4) 0 (0) 0 (0) 0 (0) 5 (12.8) 0 (0)
Non-haematological toxicity
Diarrhoea 42 (53.2) 4 (5.1) 21 (52.5) 1 (2.5) 21 (53.8) 3 (7.7)
Nausea/vomiting 35 (44.3) 0 (0) 19 (47.5) 0 (0) 16 (41) 0 (0)
Mucositis 25 (31.6) 1 (1.3) 13 (32.5) 1 (2.5) 12 (30.8) 0 (0)
Anorexia 22 (27.8) 0 (0) 8 (20) 0 (0) 14 (35.9) 0 (0)
Asthenia 54 (68.4) 4 (5.1) 26 (65) 2 (5) 28 (71.8) 2 (5.1)
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limitations of our study should be considered. In addition to
those previously mentioned concerning the early termination
due to low accrual, there was an imbalance between experi-
mental and control arms regarding the UGT1A1*1/*1 and *1/*28
genotypes and tumour sidedness, which could have favoured
the experimental arm. Therefore, UGT1A1 genotype and primary
tumour location should have been included as stratification
factors to avoid bias that could have influenced the results in
survival or disease control rates. Moreover, lower doses than in
our previous phase I study were used and the FOLFIRI schedule
is now given together with biologics in the first-line setting for
most mCRC patients, which limits the incorporation of high
doses of irinotecan regimens in clinical practice. Regarding
toxicity aspects, current evidence highlights the association
between dihydropyrimidine dehydrogenase deficiency and
an increased risk of fluoropyrimidine-related toxicity.25 The
additive value of combined UGT1A1/DPYD genotype analysis
could improve the safety of irinotecan plus fluoropyrimidine
combinations and should be considered in further studies using
these drugs.
To conclude, the findings from our study confirm the safety of
chemotherapy with HD-FOLFIRI and indicate that this strategy,
although does not show an improvement in survival, improves
ORR. A randomised phase II–III study is needed to validate
irinotecan intensification according to UGT1A1 pharmacogenetic
status combined with a biological drug adapted to RAS status.
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